“Clinical Impact of two Different Diagnostic Strategies in the First- and Second-Line Treatment of Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer”, FE, vol. 21, no. 1, Feb. 2020, doi: 10.7175/fe.v21i1.1450.